Yin and yang of tumor inflammation: How innate immune suppressors shape the tumor microenvironments

International Journal of Cancer

Volumn 135, Issue 6, 2014, Pages 1277-1285

  Jinushi, Masahisa ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

biomarker; innate immunity; tumor immunosurveillance; tumor inflammation; tumor microenvironments

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; CRYOPYRIN; DAMAGE ASSOCIATED MOLECULAR PATTERN PROTEIN; DEUBIQUITINATION ENZYME; ENZYME; INNATE IMMUNE SUPPRESSOR; PATTERN RECOGNITION RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CARCINOGENICITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG RESPONSE; GROWTH RATE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

BIOMARKER; INNATE IMMUNITY; TUMOR IMMUNOSURVEILLANCE; TUMOR INFLAMMATION; TUMOR MICROENVIRONMENTS;

HUMANS; IMMUNITY, INNATE; INFLAMMATION; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84904039152     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28626     Document Type: Review

References (84)

1. Takeuchi O, Akira S,. Pattern recognition receptors and inflammation. Cell 2010; 40: 805-20.
2. Gross O, Thomas CJ, Guarda G, et al. The inflammasome: an integrated view. Immunol Rev 2011; 243: 136-51.
3. Rakoff-Nahoum S, Medzhitov R,. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9: 57-63.
4. Lujambio A, Akkari L, Simon J, et al. Non-cell-autonomous tumor suppression by p53. Cell 2013; 153: 449-60.
5. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H,. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31: 413-41.
6. Hanahan D, Coussens LM,. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-22.
7. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436-44.
8. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
9. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
10. Biswas SK, Mantovani A,. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889-96.
11. Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860-75.
12. Jinushi M, Yagita H, Yoshiyama H, et al. Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells. Trends Mol Med 2013; 19: 536-45.
13. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
14. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-91.
15. Vacchelli E, Galluzzi L, Rousseau V, et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology 2012; 1: 271-8.
16. Krieg AM,. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117: 1184-94.
17. Seya T, Matsumoto M,. The extrinsic RNA-sensing pathway for adjuvant immunotherapy of cancer. Cancer Immunol Immunother 2009; 58: 1175-84.
18. Yu P, Lübben W, Slomka H, et al. Nucleic acid-sensing toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity 2012; 37: 867-79.
19. Yoneyama M, Fujita T,. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev 2009; 227: 54-65.
20. Poeck H, Besch R, Maihoefer C, et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008; 14: 1256-63.
21. Besch R, Poeck H, Hohenauer T, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 2009; 119: 2399-411.
22. Ishikawa H, Ma Z, Barber GN,. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009; 461: 788-92.
23. Fuertes MB, Woo SR, Burnett B, et al. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013; 34: 67-73.
24. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-8.
25. Bruchard M, Mignot G, Derangère V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19: 57-64.
26. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573-7.
27. Saitoh T, Fujita N, Jang MH, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008 13; 456: 264-8.
28. Dupaul-Chicoine J, Yeretssian G, Doiron K, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010; 32: 367-78.
29. Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-16.
30. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007; 133: 1869-81.
31. Kim S, Takahashi H, Lin WW, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-6.
32. West XZ, Malinin NL, Merkulova AA, et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 2010; 467: 972-6.
33. Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012; 109: E2110-6.
34. Belmont L, Rabbe N, Antoine M, et al. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. Int J Cancer 2013;doi: 10.1002/ijc.28413.
35. González-Reyes S, Fernández JM, González LO, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 2011; 60: 217-26.
36. Huang L, Li L, Lemos H, et al. DNA sensing via STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J Immunol 2013; 191: 3509-13.
37. Allen IC, TeKippe EM, Woodford RM, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207: 1045-56.
38. Huber S, Gagliani N, Zenewicz LA, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012; 491: 259-63.
39. Chow MT, Sceneay J, Paget C, et al. NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res 2012; 72: 5721-32.
40. van Deventer HW, Burgents JE, Wu QP, et al. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res 2010; 70: 10161-9.
41. Kondo T, Kawai T, Akira S,. Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol 2012; 33: 449-58.
42. Liew FY, Xu D, Brint EK, et al. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5: 446-58.
43. Sun H, Gong S, Carmody RJ, et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 2008; 133: 415-26.
44. Kobayashi K, Hernandez LD, Galán JE, Janeway CA Jr, Medzhitov R, Flavell RA,. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110: 191-202.
45. Xia X, Cui J, Wang HY, et al. NLRX1 negatively regulates TLR-induced NF-κB signaling by targeting TRAF6 and IKK. Immunity 2011; 34: 843-53.
46. Cui J, Zhu L, Xia X, et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 2010; 141: 483-96.
47. Ananieva O, Darragh J, Johansen C, et al. The kinases MSK1 and MSK2 act as negative regulators of toll-like receptor signaling. Nat Immunol 2008; 9: 1028-36.
48. Carmody RJ, Ruan Q, Palmer S, et al. Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade. Science 2007; 317: 675-8.
49. Saijo K, Winner B, Carson CT, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009; 137: 47-59.
50. Matsushita K, Takeuchi O, Standley DM, et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 2009; 458: 1185-90.
51. Gus-Brautbar Y, Johnson D, Zhang L, et al. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol Cell 2012; 45: 610-8.
52. Pérez-Cadahía B, Drobic B, Espino PS, et al. Role of MSK1 in the malignant phenotype of Ras-transformed mouse fibroblasts. J Biol Chem 2011; 286: 42-9.
53. Ben-Neriah Y,. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002; 3: 20-6.
54. Ma A, Malynn BA,. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol 2012; 12: 774-85.
55. Sun SC.CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010; 17: 25-34.
56. Nakayama KI, Nakayama K,. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-81.
57. Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206: 981-9.
58. Yoshimura A, Naka T, Kubo M,. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7: 454-65.
59. Rigby RJ, Simmons JG, Greenhalgh CJ, et al. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 2007; 26: 4833-41.
60. Zhou H, Miki R, Eeva M, et al. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res 2007; 13: 2344-53.
61. Rothlin CV, Ghosh S, Zuniga EI, et al. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007; 131: 1124-36.
62. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
63. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459: 712-6.
64. Novak U, Rinaldi A, Kwee I, et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009; 113: 4918-21.
65. Trompouki E, Hatzivassiliou E, Tsichritzis T, et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424: 793-6.
66. Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumor-suppressor gene. Nat Genet 2000; 25: 160-5.
67. Iliopoulos D, Jaeger SA, Hirsch HA, et al. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39: 493-506.
68. Nikolaou K, Tsagaratou A, Eftychi C, et al. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 2012; 21: 738-50.
69. Kayagaki N, Phung Q, Chan S, et al. DUBA: a deubiquitinase that regulates type I interferon production. Science 2007; 318: 1628-32.
70. Zhou F, Zhang X, van Dam H, et al. Ubiquitin-specific protease 4 mitigates Toll-like/interleukin-1 receptor signaling and regulates innate immune activation. J Biol Chem 2012; 287: 11002-10.
71. Zhang L, Zhou F, Drabsch Y, et al. USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat Cell Biol 2012; 14: 717-26.
72. Anderson AC,. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 2012; 24: 213-6.
73. Chiba S, Baghdadi M, Akiba H, et al. Tumor-infiltrating dendritic cells suppress nucleic acid-mediated innate immune responses through the interaction between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13: 832-42.
74. Tang D, Lotze MT,. Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol 2012; 13: 808-10.
75. Rothlin CV, Lemke G,. TAM receptor signaling and autoimmune disease. Curr Opin Immunol 2010; 22: 740-6.
76. Bhattacharyya S, Zagõrska A, Lew ED, et al. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 2013; 14: 136-47.
77. Chen J, Carey K, Godowski PJ,. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 1997; 14: 2033-9.
78. Ammoun S, Provenzano L, Zhou L, et al. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene 2013;doi: 10.1038/onc.2012.587.
79. Chen GY, Tang J, Zheng P, et al. vCD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009; 323: 1722-5.
80. Liu Y, Chen GY, Zheng P,. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends Immunol 2009; 30: 557-61.
81. Hoffmann A, Kerr S, Jellusova J, et al. Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat Immunol 2007; 8: 695-704.
82. Chen W, Han C, Xie B, et al. Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell 2013; 152: 467-78.
83. Han C, Jin J, Xu S, et al. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol 2010; 11: 734-42.
84. de Visser KE, Eichten A, Coussens LM,. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.